Similar Articles |
|
The Motley Fool February 27, 2007 Brian Lawler |
PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note. |
The Motley Fool August 29, 2007 Brian Lawler |
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. |
The Motley Fool April 27, 2007 Brian Lawler |
PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note. |
The Motley Fool April 14, 2008 Brian Lawler |
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business. |
The Motley Fool July 14, 2005 Charly Travers |
Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders. |
The Motley Fool September 24, 2007 Brian Lawler |
Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note. |
The Motley Fool March 15, 2005 Charly Travers |
PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note. |
The Motley Fool August 5, 2005 Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. |
The Motley Fool August 8, 2007 Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool May 3, 2005 Charly Travers |
PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner. |
The Motley Fool February 6, 2008 Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool July 12, 2007 Brian Lawler |
Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried. |
The Motley Fool July 9, 2004 Charly Travers |
Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL. |
The Motley Fool September 28, 2007 Brian Lawler |
Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs. |
The Motley Fool November 12, 2007 Brian Lawler |
What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note. |
The Motley Fool March 16, 2007 Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool May 30, 2008 Brian Lawler |
PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs. |
The Motley Fool January 26, 2005 Charly Travers |
Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock. |
The Motley Fool August 21, 2008 Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool July 27, 2007 Brian Lawler |
Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance. |
The Motley Fool April 28, 2011 Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. |
The Motley Fool March 5, 2008 Brian Lawler |
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring. |
The Motley Fool May 7, 2008 Brian Lawler |
PDL Delivers a Dividend The drugmaker's investors get a hefty payout. |
The Motley Fool October 15, 2007 Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool August 4, 2004 Charly Travers |
Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not. |
The Motley Fool November 6, 2006 Brian Lawler |
Mixed Feelings About PDL The biopharmaceutical's third-quarter results look fine on the surface, but does deeper digging reveal some reasons for investors to be concerned? |
The Motley Fool December 13, 2004 Charly Travers |
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success. |
The Motley Fool December 18, 2007 Brian Lawler |
PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note. |
The Motley Fool November 27, 2006 Brian Lawler |
Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note. |
The Motley Fool August 21, 2007 Brian Lawler |
Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year. |
The Motley Fool August 3, 2005 Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
The Motley Fool August 22, 2006 Brian Lawler |
Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company. |
The Motley Fool January 12, 2005 Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool August 18, 2008 Brian Lawler |
When Breaking Up Isn't Hard to Do PDL BioPharma and Enzon are the latest biotechs looking to spin off parts of their business. |
The Motley Fool November 25, 2008 Brian Orelli |
Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial. |
The Motley Fool July 26, 2006 Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. |
The Motley Fool November 2, 2004 Charly Travers |
Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth. |
The Motley Fool September 26, 2007 Brian Lawler |
Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma. |
The Motley Fool February 25, 2008 Brian Lawler |
A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer. |
The Motley Fool January 29, 2008 Brian Lawler |
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. |
The Motley Fool June 29, 2007 Brian Lawler |
Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note. |
The Motley Fool April 13, 2007 Brian Lawler |
Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note. |
The Motley Fool March 29, 2007 Brian Lawler |
Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note. |
The Motley Fool July 14, 2005 Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
The Motley Fool July 10, 2008 Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
The Motley Fool May 21, 2004 Charly Travers |
Protein Design Labs' Mixed Results Protein Design Labs' Nuvion looks like a winner, while other drugs stumble. Nuvion is in early clinical development for the treatment of severe ulcerative colitis and so far the results seem particularly compelling. |
The Motley Fool August 29, 2006 Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool July 15, 2008 Brian Lawler |
Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings? |
The Motley Fool April 14, 2008 Brian Lawler |
Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results. |
The Motley Fool March 17, 2008 Brian Lawler |
Genentech Takes Center Stage There might be more partnerships in store for this drugmaker. |